Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

Jolene R. Bowers; Elizabeth M. Driebe; Jennifer L. Nibecker; Bette R. Wojack; Derek S. Sarovich; Ada H. Wong; Pius M. Brzoska; Nathaniel Hubert; Andrew Knadler; Lindsey M. Watson; David M. Wagner; Manohar R. Furtado; Michael Saubolle; David M. Engelthaler; Paul S. Keim

doi:10.1186/1471-2180-12-12

Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

Jolene R. Bowers, Elizabeth M. Driebe, Jennifer L. Nibecker, Bette R. Wojack, Derek S. Sarovich, Ada H. Wong, Pius M. Brzoska, Nathaniel Hubert, Andrew Knadler, Lindsey M. Watson, David M. Wagner, Manohar R. Furtado, Michael Saubolle, David M. Engelthaler, Paul S. Keim

Biological Sciences

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them. Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan ^19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains. Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.

Original language	English (US)
Article number	12
Journal	BMC microbiology
Volume	12
DOIs	https://doi.org/10.1186/1471-2180-12-12
State	Published - 2012

ASJC Scopus subject areas

Microbiology
Microbiology (medical)

Access to Document

10.1186/1471-2180-12-12

Cite this

Bowers, J. R., Driebe, E. M., Nibecker, J. L., Wojack, B. R., Sarovich, D. S., Wong, A. H., Brzoska, P. M., Hubert, N., Knadler, A., Watson, L. M., Wagner, D. M., Furtado, M. R., Saubolle, M., Engelthaler, D. M., & Keim, P. S. (2012). Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona. BMC microbiology, 12, Article 12. https://doi.org/10.1186/1471-2180-12-12

Bowers, JR, Driebe, EM, Nibecker, JL, Wojack, BR, Sarovich, DS, Wong, AH, Brzoska, PM, Hubert, N, Knadler, A, Watson, LM, Wagner, DM, Furtado, MR, Saubolle, M, Engelthaler, DM & Keim, PS 2012, 'Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona', BMC microbiology, vol. 12, 12. https://doi.org/10.1186/1471-2180-12-12

@article{4bab7eb4d2704b36bc039f09e1faadb8,

title = "Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona",

abstract = "Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them. Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan 19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains. Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.",

author = "Bowers, {Jolene R.} and Driebe, {Elizabeth M.} and Nibecker, {Jennifer L.} and Wojack, {Bette R.} and Sarovich, {Derek S.} and Wong, {Ada H.} and Brzoska, {Pius M.} and Nathaniel Hubert and Andrew Knadler and Watson, {Lindsey M.} and Wagner, {David M.} and Furtado, {Manohar R.} and Michael Saubolle and Engelthaler, {David M.} and Keim, {Paul S.}",

note = "Funding Information: Special thanks are in order for TGen{\textquoteright}s administrative staff, Tricia O{\textquoteright}Reilly and Michael Bork, for their continual support of our scientific endeavors. The project described was supported by award number U01AI066581 and 1R01AI090782-01 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.",

year = "2012",

doi = "10.1186/1471-2180-12-12",

language = "English (US)",

volume = "12",

journal = "BMC microbiology",

issn = "1471-2180",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

AU - Bowers, Jolene R.

AU - Driebe, Elizabeth M.

AU - Nibecker, Jennifer L.

AU - Wojack, Bette R.

AU - Sarovich, Derek S.

AU - Wong, Ada H.

AU - Brzoska, Pius M.

AU - Hubert, Nathaniel

AU - Knadler, Andrew

AU - Watson, Lindsey M.

AU - Wagner, David M.

AU - Furtado, Manohar R.

AU - Saubolle, Michael

AU - Engelthaler, David M.

AU - Keim, Paul S.

N1 - Funding Information: Special thanks are in order for TGen’s administrative staff, Tricia O’Reilly and Michael Bork, for their continual support of our scientific endeavors. The project described was supported by award number U01AI066581 and 1R01AI090782-01 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

PY - 2012

Y1 - 2012

N2 - Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them. Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan 19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains. Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.

AB - Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them. Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan 19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains. Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.

UR - http://www.scopus.com/inward/record.url?scp=84855882958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855882958&partnerID=8YFLogxK

U2 - 10.1186/1471-2180-12-12

DO - 10.1186/1471-2180-12-12

M3 - Article

C2 - 22251616

AN - SCOPUS:84855882958

SN - 1471-2180

VL - 12

JO - BMC microbiology

JF - BMC microbiology

M1 - 12

ER -

Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this